Limited dosage for HES?

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie, Supplement

Volumn 36, Issue 2, 2001, Pages

  Boldt, J ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; AMYLOPECTIN; DEXTRAN; GELATIN; HETASTARCH; HUMAN ALBUMIN;

BLOOD TRANSFUSION; COLLOID; CRITICAL ILLNESS; DOSE CALCULATION; ENZYME DEGRADATION; GLOMERULUS FILTRATION; HUMAN; HYPOVOLEMIA; INTENSIVE CARE; MOLECULAR WEIGHT; NONHUMAN; PATIENT MONITORING; SHORT SURVEY; SIDE EFFECT;

COLLOIDS; DRUG STORAGE; HETASTARCH; HUMANS; KIDNEY; PLASMA SUBSTITUTES;

EID: 0035179991     PISSN: 14307790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. A new debate: Colloid versus colloid?
2. Clinical use of hydroxyethyl starches
3. Hydroxethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis
4. Präoperative Eigenblutspende, der Einfluss von Hydroxethylstärke auf Retikuloendothelialsystem und Opsonine
5. Pharmacokinetics and tolerability of a new hydroxyethylstarch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solution in healthy volunteers
6. Pathophysiology and prevention of dextran-40-induced anuria
7. Acute renal failure precipitated by elevated colloid osmotic pressure
8. Dextran-40, acute renal failure, and elevated plasma oncotic pressure
9. Elevated urinary specific gravity in acute oligure renal failure due to hetastarch administration
10. Hydroxyethyl starch and osmotic-nephrosis-like lesions in kidney transplantation
11. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients
12. Volume therapy in the critically ill: Is there a difference?